Arteaga CL - Search Results

1

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Mayer IA, et al. Among authors: arteaga cl. J Clin Oncol. 2014 Apr 20;32(12):1202-9. doi: 10.1200/JCO.2013.54.0518. Epub 2014 Mar 24. J Clin Oncol. 2014. PMID: 24663045 Free PMC article. Clinical Trial.

2

The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

Arteaga CL. Arteaga CL. J Clin Oncol. 2001 Sep 15;19(18 Suppl):32S-40S. J Clin Oncol. 2001. PMID: 11560969 Review.

3

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Moulder SL, et al. Among authors: arteaga cl. Cancer Res. 2001 Dec 15;61(24):8887-95. Cancer Res. 2001. PMID: 11751413

4

Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

Kurokawa H, Arteaga CL. Kurokawa H, et al. Among authors: arteaga cl. Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916237 Review.

5

HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.

Arteaga CL, Moulder SL, Yakes FM. Arteaga CL, et al. Semin Oncol. 2002 Jun;29(3 Suppl 11):4-10. doi: 10.1053/sonc.2002.34047. Semin Oncol. 2002. PMID: 12138392 Review.

6

Epidermal growth factor receptor dependence in human tumors: more than just expression?

Arteaga CL. Arteaga CL. Oncologist. 2002;7 Suppl 4:31-9. doi: 10.1634/theoncologist.7-suppl_4-31. Oncologist. 2002. PMID: 12202786 Free article. Review.

7

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia.

Arteaga CL. Arteaga CL. Semin Oncol. 2002 Oct;29(5 Suppl 14):3-9. doi: 10.1053/sonc.2002.35642. Semin Oncol. 2002. PMID: 12422308 Review.

8

Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.

Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Come SE, et al. Among authors: arteaga cl. Clin Cancer Res. 2003 Jan;9(1 Pt 2):443S-6S. Clin Cancer Res. 2003. PMID: 12538498 Review. No abstract available.

9

ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.

Kurokawa H, Arteaga CL. Kurokawa H, et al. Among authors: arteaga cl. Clin Cancer Res. 2003 Jan;9(1 Pt 2):511S-5S. Clin Cancer Res. 2003. PMID: 12538508 Review.

10

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.

Arteaga CL. Arteaga CL. Breast Cancer Res. 2003;5(2):96-100. doi: 10.1186/bcr574. Epub 2003 Feb 3. Breast Cancer Res. 2003. PMID: 12631388 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

416 results

Search Page